Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$28.05 USD
-0.17 (-0.60%)
Updated Oct 17, 2024 03:59 PM ET
After-Market: $28.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.05 USD
-0.17 (-0.60%)
Updated Oct 17, 2024 03:59 PM ET
After-Market: $28.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Why Is PRA Group (PRAA) Down 10.4% Since Last Earnings Report?
by Zacks Equity Research
PRA Group (PRAA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
GBOOY or RPRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
Royalty Pharma (RPRX) Matches Q4 Earnings Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 0% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Royalty Pharma (RPRX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.82% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Phillips Edison & Company, Inc. (PECO) Q3 FFO and Revenues Top Estimates
by Zacks Equity Research
Phillips Edison & Company, Inc. (PECO) delivered FFO and revenue surprises of 9.43% and 2.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Jackson Financial (JXN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Jackson Financial (JXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
by Zacks Equity Research
Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.
Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline
by Zacks Equity Research
Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.28% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Regional Management (RM) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Regional Management (RM) delivered earnings and revenue surprises of 15.89% and 0.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Jackson Financial (JXN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Jackson Financial (JXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Primis Financial (FRST) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Primis Financial (FRST) delivered earnings and revenue surprises of 14.29% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
by Zacks Equity Research
Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.
Royalty Pharma (RPRX) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Royalty Pharma (RPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Royalty Pharma (RPRX) Lags Q1 Earnings Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of -15.28% and 3.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synchrony (SYF) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Synchrony (SYF) delivered earnings and revenue surprises of 0.68% and 2.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?